Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page
- Check4 days agoChange DetectedThe page's Locations section has been expanded to include new sites across the United States and international locations such as Australia and European regions. This broadens the list of enrolling centers and may affect where patients can participate.SummaryDifference2%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedPublications note updated to state that PubMed entries are automatically filled from PubMed and may or may not pertain to the study, replacing the previous wording. The revision/version tag was updated to v3.3.2.SummaryDifference0.0%

- Check40 days agoChange DetectedA government funding status notice was removed from the page; this site-wide operational notice described potential delays and updated operating status for the NIH Clinical Center. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page content and structure appear unchanged; no additions or deletions were detected.SummaryDifference0.2%

- Check83 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. Overall, the page now communicates current operating status and a newer version rather than the old one.SummaryDifference2%

- Check90 days agoChange DetectedAppended version label (v3.1.0) and removal of multiple drug-safety related sections, indicating content consolidation and reorganization rather than new substantive content.SummaryDifference0.3%

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.